Eli Lilly (NYSE: NYSE:LLY) said on Tuesday that it has launched Lilly TuneLab, a new platform that utilizes artificial intelligence and machine learning (AI/ML) to assist biotech firms in drug discovery.
This platform offers access to models developed from research data gathered by Lilly over the years.
The initial set of AI models released by Lilly is estimated to contain proprietary data valued at over $1B, the company said.
Looking ahead, Lilly plans to enhance the platform by incorporating additional features, including in vivo predictive models for small molecules, which will be available exclusively through Lilly TuneLab.